An update on serum amyloid A–LDL and its potential use for dyslipidemic patients receiving lipid-modulating treatment

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Lipidology

• Publication date

  2013-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/clp.13.41
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of fibrate treatment in dyslipidemia: an overview.

  2013cited by this paper
• Ezetimibe therapy for dyslipidemia: an update.

  2013cited by this paper
• Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis

  2012cited by this paper
• Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.

  2012cited by this paper
• Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials

  2012cited by this paper
• Omega-3 fatty acids and cardioprotection-IIb or not IIb?

  2012cited by this paper
• Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients

  2012cited by this paper
• Pitavastatin: a new option for the reduction of cardiovascular risk factors

  2012cited by this paper
• Ezetimibe therapy: mechanism of action and clinical update

  2012cited by this paper
• Serum amyloid A in atherosclerosis

  2011cited by this paper
• Serum Amyloid a Low-Density Lipoprotein Levels and Smoking Status in Obese Japanese Patients

  2011cited by this paper
• Pitavastatin: novel effects on lipid parameters.

  2011cited by this paper
• Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress.

  2011cited by this paper
• Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.

  2011cited by this paper
• Remnant-like particle cholesterol and serum amyloid A-low-density lipoprotein levels in obese subjects with metabolic syndrome.

  2011cited by this paper
• Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome.

  2011cited by this paper
• Are All Statins the Same?

  2011cited by this paper
• Signaling mechanisms for oxidized LDL-induced oxidative stress and the upregulation of plasminogen activator inhibitor-I in vascular cells

  2010cited by this paper
• Clinical Significance of the Cardio-Ankle Vascular Index (CAVI) in Hypertension

  2010cited by this paper
• Oxidized low-density lipoprotein and atherosclerosis.

  2010cited by this paper
• Bezafibrate and serum amyloid A--low-density lipoprotein complex in patients with type 2 diabetes mellitus and hypertriglyceridemia.

  2010cited by this paper
• Inflammation in atherosclerosis: transition from theory to practice.

  2010cited by this paper
• The potential of serum amyloid A–LDL as a novel biomarker for cardiovascular disease risk

  2010cited by this paper
• Do structural differences in statins correlate with clinical efficacy?

  2010cited by this paper
• A novel oxidized low-density lipoprotein marker, serum amyloid A-LDL, is associated with obesity and the metabolic syndrome.

  2009cited by this paper
• The effects of lifestyle modification on a new oxidized low-density lipoprotein marker, serum amyloid A-LDL, in subjects with primary lipid disorder.

  2009cited by this paper
• Inflammatory biomarkers in coronary artery disease.

  2009cited by this paper
• Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome

  2009cited by this paper
• Measurement of plasma oxidized low-density lipoprotein and its clinical implications.

  2007cited by this paper
• Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

  2007cited by this paper
• Serum amyloid A generates high density lipoprotein with cellular lipid in an ABCA1- or ABCA7-dependent manner Published, JLR Papers in Press, April 10, 2006.

  2006cited by this paper
• A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease.

  2004cited by this paper
• Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study.

  2001cited by this paper
• Serum Amyloid A (SAA): a Concise Review of Biology, Assay Methods and Clinical Usefulness

  1999cited by this paper
• Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

  1989cited by this paper
• Book ReviewAmbulatory Pediatric Care

  1989cited by this paper
• Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.

  1985cited by this paper

• No citing papers are available for this paper.